Stockscreener 앱 받기
1.8613
6.19%
0.1013
전일 마감가:
$1.76
열려 있는:
$1.79
하루 거래량:
4.65M
Relative Volume:
1.14
시가총액:
$545.15M
수익:
-
순이익/손실:
$-63.08M
주가수익비율:
-6.8937
EPS:
-0.27
순현금흐름:
$-72.53M
1주 성능:
+11.24%
1개월 성능:
+81.45%
6개월 성능:
+220.68%
1년 성능:
+95.04%
1일 변동 폭
$1.765
$1.88
1주일 범위
$1.645
$1.90
52주 변동 폭
$0.515
$1.90
오큐젠 Stock (OCGN) Company Profile
명칭
Ocugen Inc
전화
484-328-4701
주소
11 GREAT VALLEY PARKWAY, MALVERN, PA
OCGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.865 | 549.66M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
418.32 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.91 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
459.08 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
799.73 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.31 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
오큐젠 Stock (OCGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-15 | 개시 | Maxim Group | Buy |
| 2023-03-01 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | 개시 | Mizuho | Buy |
| 2022-06-15 | 재개 | ROTH Capital | Buy |
| 2022-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-07-26 | 개시 | Noble Capital Markets | Outperform |
| 2021-06-11 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-05-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
모두보기
오큐젠 주식(OCGN)의 최신 뉴스
Ocugen, Inc. Hits New 52-Week High of $1.90, Marking Major Milestone - Markets Mojo
Ocugen to Highlight Gene Therapy Pipeline at Key Industry and Investor Conferences - MyChesCo
Published on: 2025-10-06 02:02:01 - newser.com
Automated trading signals detected on Ocugen Inc.Market Rally & Weekly Breakout Opportunity Watchlist - newser.com
Analyzing recovery setups for Ocugen Inc. investorsJuly 2025 WrapUp & Free Daily Entry Point Trade Alerts - newser.com
Real time pattern detection on Ocugen Inc. stockFed Meeting & Smart Money Movement Alerts - newser.com
Published on: 2025-10-05 03:08:53 - newser.com
What drives Ocugen Inc 2H51 stock priceBull Market Opportunities & Explosive Growth Opportunities - earlytimes.in
Is Ocugen Inc 2H51 a good long term investmentPrice Volatility Patterns & You’ll Regret Not Buying These Early - earlytimes.in
Ocugen (NASDAQ:OCGN) Hits New 52-Week HighHere's Why - MarketBeat
Published on: 2025-10-03 06:57:10 - newser.com
How Ocugen Inc. (2H51) stock moves on employment dataQuarterly Earnings Report & AI Based Buy/Sell Signal Reports - newser.com
Can Ocugen Inc. (2H51) stock sustain double digit ROE2025 Market Trends & Long-Term Growth Stock Strategies - newser.com
Regression analysis insights on Ocugen Inc. performanceTrade Volume Report & Low Risk High Reward Ideas - newser.com
How to recover losses in Ocugen Inc. stockGap Down & Entry and Exit Point Strategies - newser.com
Will Ocugen Inc. stock outperform international peers2025 Institutional Moves & Verified Entry Point Signals - newser.com
Published on: 2025-10-03 02:54:41 - newser.com
Ocugen, Inc. to Present at NobleCon20 Emerging Growth Equity Conference - MSN
Ocugen to Present at Major Biotechnology Conferences Focused on Advancements in Gene Therapies for Blindness Diseases - Quiver Quantitative
Ocugen to Present at Industry and Investor Conferences in October 2025 - GlobeNewswire
Targeting 3 BLA Submissions: Ocugen Leadership to Present Gene Therapy Vision at Major Industry Events - Stock Titan
Traders Buy High Volume of Ocugen Call Options (NASDAQ:OCGN) - MarketBeat
Ocugen Inc Stock Analysis and ForecastInsider Selling Patterns & High Return Capital Gains - earlytimes.in
Ocugen Strikes $7.5 Million Licensing Deal With Kwangdong for Gene Therapy in Korea - MSN
Ocugen, Inc. Hits New 52-Week High of $1.69, Marking Significant Milestone - Markets Mojo
Moving Out on the Risk Curve With a Small-Cap Biotech Play - TheStreet Pro
Ocugen Receives FDA Greenlight for Phase 1 Trial of Mucosal COVID-19 Vaccine - MSN
Published on: 2025-09-27 15:47:02 - newser.com
User - FinancialContent
Goldman Sachs Group Inc. Lowers Holdings in Ocugen, Inc. $OCGN - MarketBeat
Ocugen Inc 2H51 Stock Analysis and ForecastBullish Engulfing Patterns & Free Discover Massive Upside Stocks - Early Times
Ocugen at H.C. Wainwright: Progress in Gene Therapy for Blindness - Investing.com
Ocugen at H.C. Wainwright: Progress in Gene Therapy for Blindness By Investing.com - Investing.com Canada
Ocugen, Inc. Hits New 52-Week High of $1.32, Marking Significant Milestone - Markets Mojo
Ocugen, Inc. Hits New 52-Week High of $1.48, Signaling Strong Momentum - Markets Mojo
Ocugen, Inc. Hits New 52-Week High at $1.78, Marking Significant Milestone - Markets Mojo
Ocugen (NASDAQ:OCGN) Reaches New 52-Week HighTime to Buy? - MarketBeat
Ocugen Shares Surge as Strategic Shift Renews Investor Confidence - AD HOC NEWS
200,100 Shares in Ocugen, Inc. $OCGN Acquired by Procyon Advisors LLC - MarketBeat
Ocugen's (OCGN) Buy Rating Reaffirmed at Chardan Capital - MarketBeat
Ocugen reports positive data for OCU400, OCU410 - MSN
Ocugen (NASDAQ:OCGN) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Ocugen: A Retinal Disease Juggernaut In The Making (NASDAQ:OCGN) - Seeking Alpha
Ocugen Strikes $187.5 Million Licensing Deal With Kwangdong for Gene Therapy in Korea - MSN
오큐젠 (OCGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.16%
5.14%
자본화:
|
볼륨(24시간):